Updated time: 2021-12-10 10:40:26
28A-1020302
US 9447193 B2、TW I553015、EP 3123173 B1、CN ZL 2014-8-0079108.2(CN1070430125 B)
The technique have been designed and constructed a method as approach to suppressing cancer cells underlying transmembrane and coiled-coil domains protein 3 (TMCC3) inhibition through antibody against, wherein the antibody binds to an epitope in an extracellular domain of TMCC3. Furthermore, the method could serve a biomarker for breast cancer cells, as well as also be a marker for human embryonic stem cells undergoing differentiation. Our current work has already demonstrated TMCC3 may provide a new therapeutic strategy targeting cancer stem cells. Such endeavors should provide new insight into the molecular biology of breast and other cancer and CSCs and facilitate the design of therapeutic strategies targeting cancer stem cells in the future.
The possible cancer cells suppressing effects can be greatly increased by TMCC3 antibody treatment, that will be provides a potential for commercialization.
Cancer therapy
Alice L. Yu, John Yu, Ya-Hui Wang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Methods for suppressing cancer by inhibition of TMCC3